About Us

NEX-I, First-In-Class Cancer Immunotherapy Development Company

History

2022

12
  • Showcasing cutting-edge research on resistance mechanisms in a poster presentation at the ESMO I-O Congress
11
  • Professor Apotolia Maria Tsimberidou, a world-renowned clinical expert in oncology from MD Anderson, joined our distinguished Scientific Advisory Board (SAB)
10
  • Series-A Funding 22 billion KRW
05
  • Publication of ONCOKINE™ Discovery Platform, New anticancer immunotherapy strategy technology: Journal of controlled release, (IF=11.467)
  • Publication of ONCOKINE™ Discovery Platform, Tumor immune evasion mechanism study: Scientific Reports, (IF=4.996)
04
  • Execution of GLP Tox. non-clinical research CRO agreement
03
  • Renovation of R&D Center
  • Center for Laboratory Animal Research Approved by MFDS (located at the R&D center)
  • Publication of ONCOKINE™ Discovery Platform, Immunotherapy refractory mechanism study: The Journal of Clinical Investigation (IF=19.456)
01
  • Started Government grants by Asan Medical Center Bio Core Facility

2021